In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Majority of organizations are looking to increase investments in public and hybrid cloud
The partnership marks a significant milestone in integrating digital health education into medical curricula
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
The inspection was concluded with zero observations
Subscribe To Our Newsletter & Stay Updated
